Bayer AG and Kumquat Biosciences Inc. have entered into an exclusive global license and collaboration agreement to develop and commercialize Kumquat’s KRAS G12D inhibitor.
With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this time going after the KRAS pathway with a global deal that could bring Kumquat Biosciences Inc. up to $1.3 billion in payments.
Astrazeneca plc recently reported new preclinical data regarding their KRAS G12D inhibitor AZD-0022, currently in phase I/II clinical studies. The company presented the pharmacokinetic and pharmacodynamic profiling of the compound with the aim to push forward with its clinical development.
RAS G12D is one of the most frequent mutations in RAS, and when it occurs, it leaves RAS in a permanently active state, causing the cell to proliferate uncontrollably. Examples of the so-called RAS-addicted cancers are colorectal cancer or pancreatic ductal adenocarcinoma.
Researchers from Abbisko Therapeutics Inc. presented the preclinical characterization of ABSK-141, a potent bioavailable small-molecule KRAS G12D inhibitor.
The development of KRAS G12D inhibitors has proven challenging to date and, different from anti-KRAS G12C strategies, no compound targeting KRAS G12D mutation has been approved so far.
Genfleet Therapeutics (Shanghai) Co. Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to advance GFH-375 (VS-7375) into a phase I/II study in patients with advanced solid tumors with KRAS G12D mutation.
KRAS is the most commonly mutated oncogene in solid tumors. Mutations are present in about 30% of cases overall, more than 95% of pancreatic cancer cases, and about 40% of colon cancer cases.
Verastem Inc. has announced the nomination of an oral KRAS G12D inhibitor, VS-7375 (GFH-375), as the lead program from its discovery and development collaboration with Genfleet Therapeutics (Shanghai) Inc.
